An Open, Randomised, Controlled, Phase II Trial of CellProtect in Combination With Isatuximab Antibody Versus Isatuximab Antibody Alone as Maintenance Treatment in Patients With Multiple Myeloma Undergoing High Dose Treatment
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Isatuximab (Primary) ; Natural killer cell therapy (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Aug 2023 Planned number of patients changed from 60 to 62.
- 15 Aug 2023 Status changed from active, no longer recruiting to recruiting.
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.